Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Trial details
- Registry ID
- NCT07516093
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Bexobrutideg; bexobrutideg
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNCT07516093 | NRIX | Phase 3 | Recruiting | 2029-10Estimated |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)NCT07221500 | NRIX | Phase 2 | Recruiting | 2028-01Estimated |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesNCT07520006 | NRIX | Phase 1, Phase 2 | Recruiting | 2033-05Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |